BACKGROUND AND OBJECTIVES: This study implemented pharmacokinetic/pharmacodynamic modelling to support the clinical development of RBP-6000, a new, long-acting, sustained-release formulation of buprenorphine for the treatment of opioid dependence. Such a formulation could offer advantages over existing buprenorphine pharmacotherapy by improving patient compliance and reducing the diversion of the product. METHODS: A population pharmacokinetic model was developed using 36 opioid-dependent subjects who received single subcutaneous doses of RBP-6000. Another pharmacokinetic/pharmacodynamic model was developed using μ-opioid receptor occupancy (µORO) data to predict efficacy of RBP-6000 after repeated doses. It was also assessed how buprenorphine plasma concentrations were correlated with opioid withdrawal symptoms and hydromorphone agonist blockade data from 15 heroin-dependent subjects. RESULTS: The resulting pharmacokinetic model accurately described buprenorphine and norbuprenorphine plasma concentrations. A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations. Linear relationships were found among µORO, withdrawal symptoms and blockade of agonist effects. CONCLUSION: Previously published findings have demonstrated µORO ≥70 % is needed to achieve withdrawal suppression and blockade of opioid agonist subjective effects. Model simulations indicated that a 200 mg RBP-6000 dose should achieve 2–3 ng/mL buprenorphine average concentrations and desired efficacy.
RCT Entities:
BACKGROUND AND OBJECTIVES: This study implemented pharmacokinetic/pharmacodynamic modelling to support the clinical development of RBP-6000, a new, long-acting, sustained-release formulation of buprenorphine for the treatment of opioid dependence. Such a formulation could offer advantages over existing buprenorphine pharmacotherapy by improving patient compliance and reducing the diversion of the product. METHODS: A population pharmacokinetic model was developed using 36 opioid-dependent subjects who received single subcutaneous doses of RBP-6000. Another pharmacokinetic/pharmacodynamic model was developed using μ-opioid receptor occupancy (µORO) data to predict efficacy of RBP-6000 after repeated doses. It was also assessed how buprenorphine plasma concentrations were correlated with opioid withdrawal symptoms and hydromorphone agonist blockade data from 15 heroin-dependent subjects. RESULTS: The resulting pharmacokinetic model accurately described buprenorphine and norbuprenorphine plasma concentrations. A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations. Linear relationships were found among µORO, withdrawal symptoms and blockade of agonist effects. CONCLUSION: Previously published findings have demonstrated µORO ≥70 % is needed to achieve withdrawal suppression and blockade of opioid agonist subjective effects. Model simulations indicated that a 200 mg RBP-6000 dose should achieve 2–3 ng/mL buprenorphine average concentrations and desired efficacy.
Authors: Nathaniel P Katz; Edgar H Adams; James C Benneyan; Howard G Birnbaum; Simon H Budman; Ronald W Buzzeo; Daniel B Carr; Theodore J Cicero; Douglas Gourlay; James A Inciardi; David E Joranson; James Kesslick; Stephen D Lande Journal: Clin J Pain Date: 2007-02 Impact factor: 3.442
Authors: Nathaniel P Katz; Howard Birnbaum; Michael J Brennan; John D Freedman; Gary P Gilmore; Dennis Jay; George A Kenna; Bertha K Madras; Lisa McElhaney; Roger D Weiss; Alan G White Journal: Am J Manag Care Date: 2013-04 Impact factor: 2.229
Authors: Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta Journal: Neuropsychopharmacology Date: 2003-11 Impact factor: 7.853
Authors: Azmi F Nasser; Mark K Greenwald; Bradley Vince; Paul J Fudala; Philip Twumasi-Ankrah; Yongzhen Liu; J P Jones; Christian Heidbreder Journal: J Clin Psychopharmacol Date: 2016-02 Impact factor: 3.153
Authors: Sharon L Walsh; Sandra D Comer; Michelle R Lofwall; Bradley Vince; Naama Levy-Cooperman; Debra Kelsh; Marion A Coe; Jermaine D Jones; Paul A Nuzzo; Fredrik Tiberg; Behshad Sheldon; Sonnie Kim Journal: JAMA Psychiatry Date: 2017-09-01 Impact factor: 21.596
Authors: Tomoyuki Mizuno; Brooks T McPhail; Suyog Kamatkar; Scott Wexelblatt; Laura Ward; Uwe Christians; Henry T Akinbi; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2021-02 Impact factor: 6.447